Global Systemic Antibiotics Market, By Drug Class (Beta Lactam & Beta Lactamase Inhibitors, Quinolone, Macrolide, Others), Indication (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Systemic Antibiotics Market Analysis and Size
The global systemic antibiotics market is expected to witness significant growth during the forecast period. The growth of the systemic antibiotics market is accelerated by the rising cases of varied infectious diseases and developing launches in research and development activities conducted by many pharmaceuticals companies. An increase in investment in R&D for new drug development is projected to increase the global systemic antibiotics market during the forecast period. The wide use of systemic antibiotics for skin and soft tissue abscesses after incision and drainage resulted in a high rate of clinical cure. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global systemic antibiotics market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Antibiotics are indispensable medicines used for the treatment of life-threatening disorders and infections. Systemic antibiotics are kind of antibiotics used in the treatment of bacterial infections, administered orally or intravenously. These antibiotics work throughout the body and aid in elimination of infections. Amoxicillin, macrolide, tetracycline, cephalosporin, and metronidazole are the primary systemic antibiotics used to treat dental disorders including periodontal and endodontic diseases.
Systemic Antibiotics Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Million, Volumes in Units, Pricing in USD |
|
Segments Covered |
Drug Class (Beta Lactam & Beta Lactamase Inhibitors, Quinolone, Macrolide, Others), Indication (Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
ANI Pharmaceuticals, Inc. (U.S.), Fresenius SE & Co. KGaA (Germany), Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland.), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Melinta Therapeutics, Inc (U.S.), Janssen Global Services, LLC (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India) |
|
Market Opportunities |
|
Global Systemic Antibiotics Market Dynamics
Drivers
- Increased Incidence of Cancer and Infectious Diseases
Increasing cancer and other infectious diseases are expected to boost the market growth over the forecast period 2022-2029. For instance, as per the CDC reports U.S, 1,752,735 new cancer cases along with 599,589 deaths were reported in 2019. Further, according to Globocan 2020, U.K., 457,960 new cases with 179,648 deaths were reported in 2020. According to the reports, the most common types of malignancies witnessed were breast, prostate cancer and Non-Hodgkin’s lymphoma. Thus, this boosts the market growth.
- Rise in Prevalence of Chronic Diseases
Periodontal diseases, tooth loss and decay are pervasive dental disorders worldwide. For instance, it is projected that periodontal disease is extremely prevalent in the elderly population and affects 20% to 50% of the population worldwide. Furthermore, diabetic mellitus leading to diabetic foot infections, urinary tract infections, and other contagious diseases is rising across the globe. This is anticipated to boost the demand for systemic antibiotics in the upcoming years. Rise in skin infections and other chronic wounds is expected to increase demand for systemic antibiotics during the forecast period.
Opportunities
- Higher Investments in Research Activities
A rise in research and new drug development investment is projected to boost the global systemic antibiotics market during the forecast period. For instance, the U.S. invested US$ 260 Mn and US$ 410 Mn in antibiotic R&D activities in 2015 and 2016, respectively. Thus, this type of healthcare expenditure is expected to create opportunities for the market growth.
- Increasing Initiatives from Government
Several launch and implementation of numerous government initiatives such as antibiotic stewardship by CDC for the promotion of the appropriate use of antibiotics and reduction of antimicrobial resistance is expected to enlarge the global systemic antibiotics market during the forecast period.
Restraints/Challenges
- Adverse Complications of Antibiotics
The occurrence of antibiotic resistance by numerous species of bacteria and adverse reactions including allergic reactions, anaphylaxis, hypersensitivity reactions, and rashes associated with intake of systemic antibiotics, are projected to restrict the global market growth in the near future. For instance, tinnitus, pigment deposition of skin, pharyngitis, dizziness, gastrointestinal disturbances, photosensitivity caused due to tetracycline, C. difficile infection, and macrolides during acne treatment are expected to impede the growth of the global systemic antibiotics market in the next few years.
- High Cost
The huge expenditure associated with the type of systemic antibiotics such as Beta Lactam & Beta Lactamase Inhibitors, Quinolone hamper the market growth.
This global systemic antibiotics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global systemic antibiotics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Systemic Antibiotics Market
COVID-19 has left an unparalleled global public health crisis that has impacted practically every business. Its long-term consequences are expected to effect industry growth during the forecast period. Shift of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. During the pandemic, healthcare organizations avoided non-urgent medical needs. Major market players witnessed a decline in their revenue.
In the post-pandemic era, changes are witnessed as increase in the use of systemic antibiotics were on the rise. The socioeconomic stressors have also boosted the demand for these drugs. Thus, this will leave a significant impact on the narcotic drugs market.
Global Systemic Antibiotics Market Scope
The global systemic antibiotics market is segmented on the basis of indication, drug class, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Beta Lactam & Beta Lactamase Inhibitors
- Clavulanic acid
- Sulbactam
- Tazobactam
- Quinolone
- Moxifloxacin
- Ciprofloxacin
- Macrolide
- Erythromycin
- Clarithromycin
- Others
Indication
- Urinary Tract Infection
- Intra-Abdominal Infections
- Blood Stream Infections
- Clostridium Difficile Infections
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Systemic Antibiotics Market Regional Analysis/Insights
The global systemic antibiotics market is analysed and market size insights and trends are provided by indication, drug class, distribution channel and end-user as referenced above.
The major countries covered in the global systemic antibiotics market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for narcotic drugs market throughout the forecasted period due to the high prevalence of infectious diseases, sophisticated medical facilities and rise in government initiatives.
Asia-Pacific dominates the market due to the key generic players and increases focuses on the research and development activity.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Systemic Antibiotics Market Share Analysis
The global systemic antibiotics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global systemic antibiotics market.
Key players operating in the global systemic antibiotics market include:
- ANI Pharmaceuticals, Inc. (U.S.)
- Fresenius SE & Co. KGaA (Germany)
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland.)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- Abbvie, Inc (U.S.)
- Melinta Therapeutics, Inc (U.S.)
- Janssen Global Services, LLC (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Glenmark Pharmaceuticals Ltd (India)
SKU-
